Document Detail


Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
MedLine Citation:
PMID:  15694247     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The authors present here two cases of Parkinson's disease with depression refractory to SSRIs treatment, who experienced a complete remission after replacing the ongoing SSRIs with a serotonin-noradrenalin reuptake inhibitor (SNRI), milnacipran. The case reports suggest that milnacipran may be one of the treatment options for depression in patients with Parkinson's disease who had inadequate response to SSRIs. Further studies are warranted to confirm this observation.
Authors:
Hitoshi Takahashi; Mitsuhiro Kamata; Keizo Yoshida; Hisashi Higuchi; Tetsuo Shimizu
Related Documents :
19907347 - Case report: dieterich's disease in a teenage boy.
8914787 - Atheroembolic disease following administration of tissue plasminogen activator (tpa).
1645687 - Early gastric cancer arising from localized ménétrier's disease.
15673977 - Gorham disease of the spine: a case report and treatment strategies for this enigmatic ...
3753847 - Accessory tissue of the tricuspid valve protruding into the left ventricle through a se...
19054847 - Dorsal dislocations of the second to fifth carpometacarpal joints: a case report.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2004-12-29
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  29     ISSN:  0278-5846     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-02-07     Completed Date:  2005-05-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  351-3     Citation Subset:  IM    
Affiliation:
Department of Neuropsychiatry, Akita University School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. hito_takahashi@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic Uptake Inhibitors / therapeutic use*
Cyclopropanes / therapeutic use*
Depression / drug therapy*,  etiology
Female
Humans
Male
Middle Aged
Parkinson Disease / complications*
Serotonin Uptake Inhibitors / therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic Uptake Inhibitors; 0/Cyclopropanes; 0/Serotonin Uptake Inhibitors; 92623-85-3/milnacipran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Brain magnetic resonance imaging and single photon emission computerized tomography findings in a ca...
Next Document:  Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8.